[Form 3] Esperion Therapeutics, Inc. Initial Statement of Beneficial Ownership

Rhea-AI Filing Summary

Esperion Therapeutics, Inc. filed an initial ownership report for a senior executive showing no equity holdings. The filing is a Form 3 for the company’s Chief Commercial Officer, who is classified as an officer of Esperion Therapeutics, Inc. (ticker ESPR). The event date for this ownership status is listed as 11/17/2025. According to the remarks, no securities of Esperion, either direct or derivative, are beneficially owned by this reporting person as of that date.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Harlow John B. Jr.

(Last) (First) (Middle)

C/O ESPERION THERAPEUTICS, INC.

3891 RANCHERO DRIVE, SUITE 150

(Street)

ANN ARBOR MI 48108

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
11/17/2025

3. Issuer Name and Ticker or Trading Symbol
Esperion Therapeutics, Inc. [ ESPR ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Officer

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

No securities are beneficially owned.

No securities are beneficially owned.

	/s/ Sheldon L. Koenig, by power of attorney	11/17/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What does this Form 3 filing disclose for Esperion Therapeutics (ESPR)?

This Form 3 discloses the initial beneficial ownership status of Esperion Therapeutics, Inc.’s Chief Commercial Officer as of 11/17/2025, indicating that no securities are beneficially owned.

Who is the reporting person in this Esperion Therapeutics (ESPR) Form 3?

The reporting person is an officer of Esperion Therapeutics, Inc., serving as the company’s Chief Commercial Officer, as indicated in the relationship section.

Does the Chief Commercial Officer of ESPR own any Esperion shares or options according to this filing?

No. The remarks section twice states that no securities are beneficially owned, and both the non-derivative and derivative ownership tables contain no reported holdings.

What is the event date for the ownership status in this Esperion (ESPR) Form 3?

The date of the event requiring the statement is reported as 11/17/2025, which is the reference date for the ownership information in this filing.

Is this Form 3 for one person or multiple reporting persons at Esperion Therapeutics?

The filing is marked as Form filed by One Reporting Person, meaning it covers only the Chief Commercial Officer and not a group filing.

What type of securities are covered in this ESPR Form 3 ownership report?

The form covers both non-derivative securities (such as common stock) and derivative securities (such as options or warrants), but it reports that none are beneficially owned by the officer.